Becton, Dickinson and Company (NYSE:BDX) Announces Quarterly Earnings Results

Key Points

• BD beat quarterly expectations: Adjusted EPS was $4.15 versus the $4.07 consensus, while revenue reached $5.27 billion, up 5.4% year over year.
• Fiscal 2027 guidance was cautious: The company expects low-single-digit revenue growth and adjusted EPS of $13.10–$13.30, with revenue growth below expectations cited as a concern.
• BD increased shareholder returns: It raised its quarterly dividend to $1.06 per share and authorized repurchases of up to 10 million shares.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) announced its earnings results on Thursday. The medical instruments supplier reported $4.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.07 by $0.08, FiscalAI reports. The company had revenue of $5.27 billion during the quarter, compared to analyst estimates of $5.11 billion. Becton, Dickinson and Company had a net margin of 4.52% and a return on equity of 14.79%. The firm's quarterly revenue was up 5.4% compared to the same quarter last year. During the same period in the previous year, the business posted $3.96 earnings per share.

Here are the key takeaways from Becton, Dickinson and Company's conference call:

• BD reported Q4 revenue of $5.3 billion, up 5.6%, and adjusted EPS of $4.15, up 27.3%. For fiscal 2026, revenue increased 3.9% to $19.5 billion and adjusted EPS rose 6.7% to $12.70.
• Executives cited broad momentum in growth platforms, including Advanced Patient Monitoring, PureWick, biologic drug delivery, advanced tissue regeneration, and Rowa pharmacy automation. They also highlighted share gains in Alaris and strong adoption of the Incada AI platform, while noting these results reflect targeted commercial and capacity investments.
• Fiscal 2027 guidance calls for low-single-digit revenue growth and adjusted EPS of $13.10–$13.30, with operating margins roughly flat. Excluding an estimated 200-basis-point Alaris comparison headwind, revenue growth is expected to be mid-single-digit at the midpoint; Q1 growth is expected at the low end of the annual range.
• Full-year free cash flow rose 42% to $2.9 billion, and conversion improved to approximately 74%, including separation costs; BD expects another meaningful step-up in fiscal 2027. The company returned $3.6 billion to shareholders and said its capital allocation priorities include buybacks, debt reduction, and focused tuck-in acquisitions.
• BD agreed to invest $19 billion in the U.S. over several years, including $3 billion for manufacturing expansion; management said this is a reprioritization of planned investment, not incremental spending. Potential relief from future Section 232 tariffs is not included in guidance and depends on final rules and the company meeting agreed milestones.

Becton, Dickinson and Company Stock Down 0.6%

NYSE:BDX traded down $1.28 during trading hours on Friday, reaching $212.27. The company's stock had a trading volume of 2,172,550 shares, compared to its average volume of 1,599,485. The company has a market capitalization of $58.49 billion, a P/E ratio of 15.28, a price-to-earnings-growth ratio of 13.39 and a beta of 0.22. The company has a debt-to-equity ratio of 0.55, a quick ratio of 0.51 and a current ratio of 0.87. Becton, Dickinson and Company has a 12 month low of $137.35 and a 12 month high of $214.88. The stock has a 50 day moving average price of $188.17 and a two-hundred day moving average price of $170.28.

Becton, Dickinson and Company Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, December 31st. Investors of record on Thursday, December 10th will be issued a dividend of $1.06 per share. The ex-dividend date of this dividend is Thursday, December 10th. This is a positive change from Becton, Dickinson and Company's previous quarterly dividend of $1.05. This represents a $4.24 annualized dividend and a yield of 2.0%. Becton, Dickinson and Company's dividend payout ratio is 126.51%.

Insider Buying and Selling at Becton, Dickinson and Company

In related news, EVP Michael Feld sold 165 shares of the business's stock in a transaction on Wednesday, August 26th. The stock was sold at an average price of $188.49, for a total transaction of $31,100.85. Following the transaction, the executive vice president directly owned 19,720 shares in the company, valued at $3,717,022.80. The trade was a 0.83% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Roland Goette sold 2,438 shares of the business's stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $180.84, for a total value of $440,887.92. Following the sale, the executive vice president owned 14,856 shares in the company, valued at $2,686,559.04. The trade was a 14.10% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 6,907 shares of company stock valued at $1,269,128. 0.40% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on BDX shares. Royal Bank Of Canada lifted their price objective on Becton, Dickinson and Company from $190.00 to $225.00 and gave the company a "sector perform" rating in a research report on Friday. Piper Sandler lifted their target price on Becton, Dickinson and Company from $175.00 to $200.00 and gave the stock a "neutral" rating in a report on Friday. UBS Group assumed coverage on Becton, Dickinson and Company in a research report on Tuesday, July 28th. They set a "buy" rating and a $190.00 target price for the company. Wolfe Research began coverage on shares of Becton, Dickinson and Company in a report on Tuesday, October 20th. They issued an "outperform" rating on the stock. Finally, Zacks Research upgraded Becton, Dickinson and Company from a "hold" rating to a "strong-buy" rating in a report on Wednesday, October 21st. One analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, eight have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $193.67.

Key Stories Impacting Becton, Dickinson and Company

Here are the key news stories impacting Becton, Dickinson and Company this week:

• Positive Sentiment: BD reported Q4 adjusted earnings of $4.15 per share and revenue of $5.27 billion, topping analyst expectations; revenue rose 5.4% year over year. BD fiscal 2026 results
• Positive Sentiment: The board raised the quarterly dividend 1% to $1.06 per share and authorized repurchases of up to 10 million shares, or about 3.6% of shares outstanding. Dividend increase and share repurchase authorization
• Positive Sentiment: Citigroup raised its price target to $241 and assigned a “buy” rating; Evercore ISI also lifted its target, to $230 from $210. Citigroup analyst rating Evercore ISI price target
• Neutral Sentiment: RBC raised its target to $225 but kept a “sector perform” rating, while Piper Sandler raised its target to $200 and maintained “neutral”—below the stock’s recent trading level. RBC analyst rating Piper Sandler price target
• Negative Sentiment: The main concern is the fiscal 2027 outlook: coverage reports say revenue-growth guidance came in just below expectations, tempering the impact of the Q4 beat and prompting investor concern. Fiscal 2027 guidance coverage

Becton, Dickinson and Company declared that its Board of Directors has approved a share repurchase program on Thursday, November 5th that allows the company to repurchase 10,000,000 outstanding shares. This repurchase authorization allows the medical instruments supplier to purchase up to 3.6% of its shares through open market purchases. Share repurchase programs are typically an indication that the company's board of directors believes its stock is undervalued.

About Becton, Dickinson and Company

Becton, Dickinson and Company, commonly known as BD, is a global medical technology company that develops and manufactures products used in healthcare, clinical laboratories and life sciences research. Founded in 1897, the company has a long history of producing medical devices and supplies.

BD's products include syringes, needles, infusion systems and medication-management technologies, as well as equipment and supplies for collecting and processing clinical specimens. The company also provides diagnostic systems, laboratory instruments and tools used in areas such as cell analysis and biomedical research.

Its offerings serve hospitals, clinics, laboratories, researchers and pharmaceutical companies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.